Hashimoto's Thyroiditis (Investigational Cervical Adjunct)

Highly investigational adjunct in stable Hashimoto's thyroiditis; case reports only; levothyroxine replacement remains primary.

Tier C — InvestigationalInvestigationalLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Patient Summary

Is this FDA-cleared for this use?: Not FDA-cleared for Hashimoto thyroiditis. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?: Tier C (investigational). No controlled trials. Evidence-based first-line management is levothyroxine replacement when hypothyroidism is biochemically confirmed (TSH above the reference range with low free T4, or TSH consistently above 10). Subclinical disease may be observed. Selenium has marginal evidence for reducing antibody titers but does not change long-term outcomes.
Main risks: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Who should not consider this: Patients with TSH greater than 10 or clearly symptomatic hypothyroidism (need levothyroxine, not leeches)
Patients planning to defer or stop thyroid hormone replacement based on leech treatment
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
Patients who are pregnant or breastfeeding (relative contraindication; insufficient safety data)
What to ask your clinician: Is my hypothyroidism mild enough that observation is appropriate, or do I need levothyroxine?
Will the leech therapy delay or replace any needed thyroid hormone replacement (it should not)?
How will thyroid function be monitored during the course?
What is the published evidence base for leeches and autoimmune thyroiditis specifically?
Could pregnancy be in my future, and how does that affect thyroid management?
What is your plan if my thyroid antibodies do not change?
When to seek urgent care: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
Severe fatigue, cold intolerance, slow heart rate, or confusion (worsening hypothyroidism)
Rapid neck swelling, difficulty swallowing or breathing (rare painful thyroiditis variant)

What this does NOT mean

It does not mean leech therapy is FDA-cleared for Hashimoto thyroiditis — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace levothyroxine replacement when hypothyroidism is biochemically present.
It does not eliminate antithyroid antibodies or stop the underlying autoimmune process.
It does not have controlled-trial evidence in Hashimoto disease.
It does not change long-term progression to clinical hypothyroidism in most patients.

Safety cross-references

Clinical Profile

Category: other
ICD-10: E06.3
Safety tier: high

Evidence Summary

Hashimoto's thyroiditis is managed with levothyroxine replacement to normalize TSH per ATA 2014 guidelines, and subclinical hypothyroidism is treated based on age, TSH level, antibody status, and symptoms. No controlled clinical trial of leech therapy for Hashimoto's thyroiditis or autoimmune thyroid antibody modification has been published; use is investigational and mechanistic only. Any proposed local antiinflammatory or lymphatic rationale is speculative and unsupported by clinical data, so the honest evidence grade is D. Cervical leech placement is anatomically risky given carotid proximity and cannot be recommended outside of a research setting.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Key Trials

Sotnikov OS et al. (2009)0

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Compressive goiter or large nodules requiring biopsy
Suspicion of thyroid malignancy
Active Graves disease or thyroid storm
Carotid disease or recent neck surgery
Anticoagulation for atrial fibrillation

Related Conditions

Metabolic Syndrome (Investigational Adjunct)

Investigational adjunct to lifestyle modification in metabolic syndrome; small case series only; weight loss, dietary modification, and pharmacotherapy remain primary.

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (Investigational Adjunct)

Investigational adjunct for ME/CFS symptom management; pacing strategies, post-exertional malaise avoidance, and individualized supportive care remain primary; graded exercise therapy is no longer recommended per updated NICE guidance.

Stage III Postsurgical Lymphedema (Highly Investigational Adjunct)

Highly investigational adjunct for advanced postsurgical lymphedema; complete decongestive therapy and (selectively) surgical options (LVA, VLNT) remain evidence-based.

Recurrent Aphthous Stomatitis (Investigational Adjunct)

Investigational adjunct for severe recurrent aphthous stomatitis; topical corticosteroids, chlorhexidine, and (for severe disease) colchicine or systemic immunomodulators remain evidence-based.